ArticleProceedings of the National Academy of Sciences of the United States of America2013

Mutant KRAS is a druggable target for pancreatic cancer.

Elina Zorde Khvalevsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.